No Data
No Data
Hubei Biocause Pharmaceutical (000627.SZ): Achieved 24.608 billion yuan in gross insurance premiums received in the first half of 2024.
On July 11, Gelunhui reported that Hubei Biocause Pharmaceutical (000627.SZ) stated on the investor interaction platform that in the first half of 2024, China Best Life Insurance will maintain a moderate business scale and continue to promote business structure optimization and asset allocation structure optimization, steadily advance asset-liability matching, continuously strengthen new technology application and talent reserve, improve the company's management system, and comprehensively enhance the company's operational capabilities. While ensuring the basic stability of premium income, according to market conditions, adjust the business rhythm and structure in a timely manner, vigorously promote the development of long-term value and risk protection type business. At present, operations of China Best Life Insurance's business
Biocause Pharmaceutical's Insurance Arm Logs 25 Billion Yuan in Annual Insurance Premium
Hubei Biocause Pharmaceutical (SHE:000627)said the annual insurance premium of subsidiary Guohua Life Insurance amounted to 24.6 billion yuan in the first half, according to the company's Monday filin
Hubei Biocause Pharmaceutical: 2024-043- Hubei Biocause Pharmaceutical's half-year performance forecast for 2024.
Hubei Biocause Pharmaceutical (stock code: 000627.SZ): The cumulative original insurance premium income of its holding subsidiary China Best Life from January to June is about 24.6 billion yuan.
On July 8th, Gelunhui reported that Hubei Biocause Pharmaceutical (000627.SZ), a controlling subsidiary, has been implementing business development in accordance with the overall concept of 'firmly transforming and developing, highlighting value growth, comprehensively enhancing capabilities, and moving towards a mature insurance enterprise', deepening the value of business and continuously promoting the optimization of business structure. The cumulative original insurance premium income from January 1st, 2024 to June 30th, 2024 was approximately RMB 24,607.559 million.
Hubei Biocause Pharmaceutical (000627.SZ) expects a loss of 420 million yuan to 330 million yuan in the first half of the year.
On July 8th, GeLongHui reported that Hubei Biocause Pharmaceutical (000627.SZ) released its performance forecast for the first half of 2024, with an expected net loss attributable to shareholders of the listed company of 0.42 billion yuan to 0.33 billion yuan, a year-on-year decrease of 124% to 76%; excluding non-recurring gains and losses, the net loss was 0.43 billion yuan to 0.34 billion yuan, a year-on-year decrease of 131% to 83%; basic loss per share was 0.085 yuan/share to 0.067 yuan/share. In the first half of 2024, the interest rate market environment continued to decline, and the company's holding subsidiary, China Best Life Insurance, was affected by the downward movement of the 750-day mobile average national bond yield curve.
Hubei Biocause Pharmaceutical (000627.SZ) appointed Chen Dali as the General Manager.
On June 27th, Gelonhui reported that the board of directors of Hubei Biocause Pharmaceutical (000627.SZ) held the seventeenth meeting of the ninth board of directors on June 27, 2024, and approved the Proposal of Appointing the General Manager of the Company. Upon proposal of the Chairman of the Board and nomination of the Nomination Committee of the Board and after its review and approval, the Board agreed to appoint Mr. Chen Dali as General Manager of the Company for a term commencing from the date of approval at the Board meeting to the expiration of the term of the ninth Board of Directors of the Company.
No Data